Sitemap > News > Cancer Immunotherapy
Displaying 1 - 50 of 1021 results
- Data Show Improved Response Rate when Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
- Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
- CytImmune Presents Positive CYT-6091 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
- IDM Pharma Presents Interim Phase II Data From EP-2101 Lung Cancer Vaccine Clinical Trial
- Introgen Reports Updated Phase 2 ADVEXIN(R) Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
- Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
- Oxford BioMedica and Sanofi-Aventis Report Encouraging New Trovax® Phase II Trial Results in Renal Cancer
- Final Data from a Phase 2 Trial Presented at ASCO Specifies Dose-dependent Activity of Adecatumumab (MT201)
- Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
- Cell Genesys and Medarex Report Follow-Up Data From a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody
- OXFORD BIOMEDICA AND SANOFI-AVENTIS REPORT NEW TROVAX® PHASE II TRIAL RESULTS IN RENAL CANCER
- Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
- Patients Who Took Investigational Melanoma Compound CP-675,206 Showed Favorable Survival Outcomes, Pfizer Says
- ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
- Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
- Antigenics’ QS-21 Stimulon Adjuvant Enters Phase 3 Clinical Trial of GlaxoSmithKline’s Novel Cancer Immunotherapeutic in Non-Small Cell Lung Cancer
- Biovest to File for Accelerated Conditional Approval of BiovaxID
- Cervarix, the GSK cervical cancer candidate vaccine, provides sustained immune response in 100 per cent of women up to 55 years of age
- Encouraging clinical activity of GSK’s novel cancer immunotherapeutic confirmed in phase II study in patients with most common form of lung cancer
- IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
- IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS WITH hPAM4 FOR PANCREATIC CANCER THERAPY
- Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
- YM BIOSCIENCES CLEARED TO INITIATE CLINICAL TRIAL OF NIMOTUZUMAB IN COLORECTAL CANCER
- FDA Accepts and Grants Priority Review of Erbitux (Cetuximab) sBLA for Overall Survival in Patients With Advanced Colorectal Cancer
- CEL-SCI Receives US FDA Orphan Drug Designation for Its Cancer Drug Multikine
- Interim Analysis of Anti-Cancer Vaccine, BiovaxID, to be Conducted
- GENMAB ANNOUNCES DEVELOPMENT PLANS FOR OFATUMUMAB
- Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
- MorphoSys Announces Clinical Milestone in Partnered Therapeutic Antibody Program - Third HuCAL-based Antibody to Begin Clinical Trials
- Pfizer Discontinues Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer
- Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
- Oncolytics Biotech Inc. Commences Patient Enrolment in U.S. Phase II Sarcoma Clinical Trial
- Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
- VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
- Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
- Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
- Cell Genesys Completes Patient Recruitment for First Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
- California Biotechnology Company Takes Aim At Pancreatic Cancer With An Advanced Phase I/Ii Clinical Trial Using Rexin-G, A Targeted Injectable Gene Delivery System
- TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment
- GERON INITIATES CLINICAL TRIAL OF TELOMERASE CANCER VACCINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA
- Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
- Phase II Study of IMC-A12 for Advanced Colorectal Cancer Has Commenced Patient Enrollment
- TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment
- Avastin receives positive opinion in Europe for first-line treatment of patients with advanced lung cancer
- Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab® for patients with malignant ascites
- ImmunoGen, Inc. Earns Milestone with Start of Trastuzumab-DM1 Phase II Testing
- YM BIOSCIENCES INITIATES PATIENT ENROLMENT IN PHASE II COLORECTAL CANCER TRIAL WITH EGFR ANTIBODY
- Antigenics Provides Update on Filing for Approval of Oncophage in Russia for the Treatment of Intermediate-Risk Kidney Cancer
- Enzon Commences Enrollment of Two Phase 1 Studies of PEG-SN38 for Advanced Solid Tumors and Lymphoma
- Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India